For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 1,553 | 1,541 | ||
| General and administrative | 1,180 | 1,164 | ||
| Total operating expenses | 2,733 | 2,705 | ||
| Loss from operations | -2,733 | -2,705 | ||
| Interest income | 59 | 17 | ||
| Other income, net | 3 | 151 | ||
| Net loss | -2,671 | -2,537 | ||
| Basic EPS | -0.06 | -0.13 | ||
| Diluted EPS | -0.06 | -0.13 | ||
| Basic Average Shares | 43,042,691 | 18,868,124 | ||
| Diluted Average Shares | 43,042,691 | 18,868,124 | ||
INTENSITY THERAPEUTICS, INC. (INTS)
INTENSITY THERAPEUTICS, INC. (INTS)